Learn More
PURPOSE This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, with erlotinib, a(More)
SummaryBackground Dacomitinib (PF-00299804) is an oral, irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases. Methods This phase I,(More)
5561 Background: PF is a potent, irreversible small molecule pan-HER tyrosine kinase inhibitor (TKI) with pre-clinical antitumor activity against EGFRvIII-mutated cell lines and xenograft models(More)